{
  "actions": [
    {
      "acted_at": "2018-07-26",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2018-07-26",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    },
    {
      "acted_at": "2018-07-27",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr6576-115",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "115",
  "cosponsors": [],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2018-07-26",
  "number": "6576",
  "official_title": "To require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "s2157-115",
      "identified_by": "CRS",
      "reason": "identical",
      "type": "bill"
    }
  ],
  "short_title": "Drug-Price Transparency in Communications Act",
  "sponsor": {
    "bioguide_id": "S001145",
    "district": "9",
    "name": "Schakowsky, Janice D.",
    "state": "IL",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2018-07-26",
  "subjects": [
    "Drug safety, medical device, and laboratory regulation",
    "Health",
    "Licensing and registrations",
    "Marketing and advertising"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2018-07-26",
    "date": "2019-08-20T19:52:14Z",
    "text": "Drug-Price Transparency in Communications Act\n\nThis bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.\n\nThe bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Drug-Price Transparency in Communications Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.",
      "type": "official"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Drug-Price Transparency in Communications Act",
      "type": "short"
    }
  ],
  "updated_at": "2023-01-11T13:41:55Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/115/hr/BILLSTATUS-115hr6576.xml"
}